title: Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature.
abstract: OBJECTIVE
  Few studies describe peptide receptor radionuclide therapy (PRRT) using (90)Y- or (177)Lu-labeled peptides in patients with recurrent meningiomas. No clinical data about (111)In-Pentetreotide in such patients are available. We report on (111)In-Pentetreotide therapy in patients with inoperable meningiomas and review the literature about PRRT of meningiomas.
  
  
  METHODS
  We reviewed clinical records of 8 patients with meningioma/meningiomatosis showing high (111)In-Pentetreotide uptake on pretherapy scintigraphy who were treated with at least one cycle of (111)In-Pentetreotide. In 2 patients, a cocktail of (111)In-Pentetreotide and beta-emitting radiolabeled peptides had been administered.
  
  
  RESULTS
  No patient experienced acute toxicity, neurological or renal function impairment. Mild transient bone marrow toxicity was observed in 4 patients. Objective partial response was observed in 2 patients, stable disease in 5 and disease progression in one. There were no statistically significant correlations between objective response and patient age, tumor WHO grade, baseline Karnofsky performance score, (111)In-Pentetreotide tumoral uptake grade, tumor/nontumor ratio, disease state at baseline, and cumulative dose.
  
  
  CONCLUSIONS
  In consideration of its efficacy and the lack of significant toxicity, PRRT of meningiomas using (111)In-Pentetreotide could be proposed even nowadays when the use of (177)Lu- or (90)Y-labeled peptides seems unsafe, namely in patients with renal impairment/toxicity.
authors.affiliation: 1 Department of Biomedical Sciences and Morphological and Functional Images, University of Messina , Messina, Italy .
authors.forename: Fabio
authors.initials: F
authors.lastname: Minutoli
authors.forename: Ernesto
authors.initials: E
authors.lastname: Amato
authors.forename: Alessandro
authors.initials: A
authors.lastname: Sindoni
authors.forename: Davide
authors.initials: D
authors.lastname: Cardile
authors.forename: Alfredo
authors.initials: A
authors.lastname: Conti
authors.forename: Astrid
authors.initials: A
authors.lastname: Herberg
authors.forename: Sergio
authors.initials: S
authors.lastname: Baldari
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008577:Meningeal Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D008579:Meningioma / Q000378:metabolism / Q000532:radiotherapy*; D008875:Middle Aged; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018000:Receptors, Peptide; D012189:Retrospective Studies; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D013004:Somatostatin; C081788:pentetreotide
keywords: 111In-Pentetreotide; meningioma; peptide receptor radionuclide therapy